Skip to main content
Erschienen in: Comparative Clinical Pathology 6/2012

01.12.2012 | Original Article

Clinical relevance of angiopoietin-1, angiopoietin-2, and their receptor Tie-2 expression in acute myeloid leukemia

verfasst von: Safaa M. El Karaksy, Nancy M. El Guindy, Heba M. Gouda, Mervat M. Khorshied, Iman A. Shaheen, Reham E. Abu Khalil, Noha Y. Ibrahim

Erschienen in: Comparative Clinical Pathology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

The angiogenic-related factors: angiopoietin-1 and -2 and their receptor Tie-2 have wide-ranging effects on tumor behavior that includes angiogenesis and, inflammation. These multifaceted pathways present a potential target in developing novel inhibition strategies for cancer therapy. The present work aimed at detecting the prevalence of expression of: angiopoietin-1, angiopoietin-2, and their receptor Tie-2 in 56 Egyptian de novo acute myeloid leukemia (AML) patients by conventional RT-PCR to verify the prognostic impact of their expression on the response to induction chemotherapy. Thirty age- and sex-matched healthy volunteers were subjected to the same analysis as a control group. High expression of angiopoietin-1 (Ang-1) was detected in the patient group but not the control group. AML patients expressing angiopoietin-2 (Ang-2) either solely or in combination with high Ang-1 and/or Tie-2 showed unfavorable response to induction chemotherapy; either failed induction or death during induction. These data provide evidence that the alternation of angiopoietin balance in favor of Ang-2 may play a critical role in the pathophysiology of AML. Furthermore, positive pre-therapeutic expression of Ang-2 indicates valiable unfavorable prognostic marker in AML patients and may be used as a prognostic tool in the risk-adaptive management of AML.
Literatur
Zurück zum Zitat Bacher U, Kern W, Schoch C et al (2006) Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 106(4):839–847PubMedCrossRef Bacher U, Kern W, Schoch C et al (2006) Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 106(4):839–847PubMedCrossRef
Zurück zum Zitat Bennett JM, Catvosky D, And Daniel MT (1985) Proposed revised criteria of the classification of acute myeloid leukemia. Ann Intern Med 103:602–625 Bennett JM, Catvosky D, And Daniel MT (1985) Proposed revised criteria of the classification of acute myeloid leukemia. Ann Intern Med 103:602–625
Zurück zum Zitat Cassileth PA, Lynch E, Hines JD et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924–1930PubMed Cassileth PA, Lynch E, Hines JD et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924–1930PubMed
Zurück zum Zitat de Bont ES, Rosati S, Jacobs S et al (2001) Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113:296–304PubMedCrossRef de Bont ES, Rosati S, Jacobs S et al (2001) Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113:296–304PubMedCrossRef
Zurück zum Zitat De Greef G, Van W, Boogarts M (2005) Criteria for defining a complete remission in acute myeloid leukemia. Br J Haematol 128(2):184PubMedCrossRef De Greef G, Van W, Boogarts M (2005) Criteria for defining a complete remission in acute myeloid leukemia. Br J Haematol 128(2):184PubMedCrossRef
Zurück zum Zitat Dong D, Ni M, Li J, Xiong S et al (2008) Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 15(68(2)):498–505CrossRef Dong D, Ni M, Li J, Xiong S et al (2008) Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 15(68(2)):498–505CrossRef
Zurück zum Zitat Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5(12):1359–1364PubMedCrossRef Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5(12):1359–1364PubMedCrossRef
Zurück zum Zitat Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552–558PubMedCrossRef Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552–558PubMedCrossRef
Zurück zum Zitat Giles FJ (2001) The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 6(Suppl 5):32–39PubMedCrossRef Giles FJ (2001) The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 6(Suppl 5):32–39PubMedCrossRef
Zurück zum Zitat Goldstone AH, Burnett AK, Wheatley K et al (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5):1302–1311PubMedCrossRef Goldstone AH, Burnett AK, Wheatley K et al (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5):1302–1311PubMedCrossRef
Zurück zum Zitat Grosicki S, Grosicka A, Hołowiecki J (2007) Clinical importance of angiogenesis and angiogenic factors in oncohematology. Wiad Lek 60(1–2):39–46PubMed Grosicki S, Grosicka A, Hołowiecki J (2007) Clinical importance of angiogenesis and angiogenic factors in oncohematology. Wiad Lek 60(1–2):39–46PubMed
Zurück zum Zitat Hatfield KJ, Hovland R, Øyan AM et al (2008) Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 22(2):287–293PubMedCrossRef Hatfield KJ, Hovland R, Øyan AM et al (2008) Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 22(2):287–293PubMedCrossRef
Zurück zum Zitat Hou HA, Choua WC, Lin LI et al (2008) Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32:904–912PubMedCrossRef Hou HA, Choua WC, Lin LI et al (2008) Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32:904–912PubMedCrossRef
Zurück zum Zitat Kümpers P, Koenecke C, Hecker H et al (2008) Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 1(112(5)):2139–2148CrossRef Kümpers P, Koenecke C, Hecker H et al (2008) Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 1(112(5)):2139–2148CrossRef
Zurück zum Zitat Lee KW, Lip GY, Blann AD (2004) Plasma angiopoietin-1,angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110(16):2355–2360PubMedCrossRef Lee KW, Lip GY, Blann AD (2004) Plasma angiopoietin-1,angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110(16):2355–2360PubMedCrossRef
Zurück zum Zitat Lee CY, Tien HF, Hu CY et al (2007) Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.Br. J Cancer 8(97(7)):877–882 Lee CY, Tien HF, Hu CY et al (2007) Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.Br. J Cancer 8(97(7)):877–882
Zurück zum Zitat Licht JD, Chomienne C, Goy A et al (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85(4):1083–1094PubMed Licht JD, Chomienne C, Goy A et al (1995) Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85(4):1083–1094PubMed
Zurück zum Zitat Loges S, Heil G, Bruweleit M et al (2005) Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 20(23(6)):1109–1117CrossRef Loges S, Heil G, Bruweleit M et al (2005) Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 20(23(6)):1109–1117CrossRef
Zurück zum Zitat MacCallum PK, Rohatiner AZ, Davis CL et al (1995) Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol 71(1):35–39PubMedCrossRef MacCallum PK, Rohatiner AZ, Davis CL et al (1995) Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol 71(1):35–39PubMedCrossRef
Zurück zum Zitat Muller A, Lange K, Gaiser T et al (2002) Expressionof angiopoietin-1 and its receptor TEK inhematopoietic cells from patients with myeloid leukemia. Leuk Res 26:163–168PubMedCrossRef Muller A, Lange K, Gaiser T et al (2002) Expressionof angiopoietin-1 and its receptor TEK inhematopoietic cells from patients with myeloid leukemia. Leuk Res 26:163–168PubMedCrossRef
Zurück zum Zitat Sampath D, Cortes J, Estrov Z et al (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107(6):2517–2524PubMedCrossRef Sampath D, Cortes J, Estrov Z et al (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107(6):2517–2524PubMedCrossRef
Zurück zum Zitat Schliemann C, Bieker R, Padro T et al (2006) Expression of angiopoietins and their receptor Tie 2 in bone marrow of patients with acute myeloid leukemia. Haemtologica 91:1203–1211 Schliemann C, Bieker R, Padro T et al (2006) Expression of angiopoietins and their receptor Tie 2 in bone marrow of patients with acute myeloid leukemia. Haemtologica 91:1203–1211
Zurück zum Zitat Schliemann C, Bieker R, Thoennissen N et al (2007) Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21(9):1901–1906PubMedCrossRef Schliemann C, Bieker R, Thoennissen N et al (2007) Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21(9):1901–1906PubMedCrossRef
Zurück zum Zitat Shim WS, Ho IA, Wong PE (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5(7):655–665PubMedCrossRef Shim WS, Ho IA, Wong PE (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5(7):655–665PubMedCrossRef
Zurück zum Zitat Stone RM, Berg DT, George SL et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98(3):548–553PubMedCrossRef Stone RM, Berg DT, George SL et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98(3):548–553PubMedCrossRef
Zurück zum Zitat Teng CL, Young JH, Hsu SL et al (2006) Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia. J Chin Med Assoc 69(11):534–537PubMedCrossRef Teng CL, Young JH, Hsu SL et al (2006) Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor, positively correlates to bone marrow vascularity in acute myeloid leukemia. J Chin Med Assoc 69(11):534–537PubMedCrossRef
Zurück zum Zitat Verstovsek S, Kantarjian H, Manshouri T et al (2002) Prognostic significance of cellular vascularendothelial growth factor expression in chronicphase chronic myeloid leukemia. Blood 99:2265–2267PubMedCrossRef Verstovsek S, Kantarjian H, Manshouri T et al (2002) Prognostic significance of cellular vascularendothelial growth factor expression in chronicphase chronic myeloid leukemia. Blood 99:2265–2267PubMedCrossRef
Zurück zum Zitat Wakabayashi M, Miwa H, Shikami M et al (2004) Autocrine pathway of angiopoietins-Tie2 system in AML cells; association with phosphatidyl-inositol 3 kinase. Hematol J 5:353–360PubMedCrossRef Wakabayashi M, Miwa H, Shikami M et al (2004) Autocrine pathway of angiopoietins-Tie2 system in AML cells; association with phosphatidyl-inositol 3 kinase. Hematol J 5:353–360PubMedCrossRef
Zurück zum Zitat Watarai M, Miwa H, Shikami M et al (2002) Expression of endothelial cell-associated molecules in AML cells. Leukemia 16:112–119PubMedCrossRef Watarai M, Miwa H, Shikami M et al (2002) Expression of endothelial cell-associated molecules in AML cells. Leukemia 16:112–119PubMedCrossRef
Metadaten
Titel
Clinical relevance of angiopoietin-1, angiopoietin-2, and their receptor Tie-2 expression in acute myeloid leukemia
verfasst von
Safaa M. El Karaksy
Nancy M. El Guindy
Heba M. Gouda
Mervat M. Khorshied
Iman A. Shaheen
Reham E. Abu Khalil
Noha Y. Ibrahim
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Comparative Clinical Pathology / Ausgabe 6/2012
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-011-1256-x

Weitere Artikel der Ausgabe 6/2012

Comparative Clinical Pathology 6/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …